| Date Filed | Type | Description |
| 01/29/2021 |
SC 13G/A
| Tekla Capital Management LLC reports a 0% stake in Zyla Life Sciences |
| 06/01/2020 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 05/22/2020 |
4
| CR Group L.P. (10% Owner) has filed a Form 4 on Zyla Life Sciences|
Txns:
| Disposed/sold 4,586,874 shares
@ $0
Disposed/sold 2,436,459 warrants
@ $0.0001, valued at
$243.6 |
|
| 05/22/2020 |
SC 13D/A
| Capital Royalty L.P. reports a 0% stake in Zyla Life Sciences |
| 05/21/2020 |
4
| McInnis Joe (Director) has filed a Form 4 on Zyla Life Sciences|
Txns:
| Disposed/sold 26,953 shares
@ $0 |
|
| 05/21/2020 |
4
| Strobeck Mark (COO) has filed a Form 4 on Zyla Life Sciences|
Txns:
| Disposed/sold 180,864 shares
@ $0
Disposed/sold 116,400 options to buy
@ $1.5, valued at
$174.6k
|
|
| 05/21/2020 |
4
| Walbert Timothy P (Director) has filed a Form 4 on Zyla Life Sciences|
Txns:
| Disposed/sold 26,953 shares
@ $0 |
|
| 05/21/2020 |
4
| Smiley Andrea Heslin (Director) has filed a Form 4 on Zyla Life Sciences|
Txns:
| Disposed/sold 26,953 shares
@ $0 |
|
| 05/21/2020 |
4
| Phillips Gary M. (Director) has filed a Form 4 on Zyla Life Sciences|
Txns:
| Disposed/sold 33,620 shares
@ $0 |
|
| 05/21/2020 |
4
| Pauls Matthew (Director) has filed a Form 4 on Zyla Life Sciences|
Txns:
| Disposed/sold 26,953 shares
@ $0 |
|
| 05/21/2020 |
4
| SMITH TODD N (President and CEO) has filed a Form 4 on Zyla Life Sciences|
Txns:
| Disposed/sold 365,500 shares
@ $0
Disposed/sold 241,500 options to buy
@ $1.5, valued at
$362.3k
Disposed/sold 180,000 options to buy
@ $2.37, valued at
$426.6k
|
|
| 05/21/2020 |
4
| TIMMINS MEGAN C. (General Counsel) has filed a Form 4 on Zyla Life Sciences|
Txns:
| Disposed/sold 107,951 shares
@ $0
Disposed/sold 84,700 options to buy
@ $1.5, valued at
$127.1k
|
|
| 05/20/2020 |
8-K
| Investor presentation|
Docs:
|
"Assertio Completed Merger with Zyla Life Sciences Trading under ASRT on Nasdaq Global Select Market Combined Company Pro Forma 2019 Net Product Sales of Approximately $128 Million 1 Upwards of $40 million in Expected Cost Synergies LAKE FOREST, Ill., -- Assertio Holdings, Inc., the successor issuer to Assertio Therapeutics, Inc., announced the closing of the merger with Zyla Life Sciences. The combined company will operate under the Assertio name and trade on Nasdaq under the ticker ASRT. The merger creates a growing commercial pharmaceutical company with neurology, inflammation and pain products. The Company now has a differentiated portfolio of non-steroidal anti-inflammatory drugs commonly used by neurologists, orthopedic surgeons, internists, women’ s health providers, podiatrists, p...",
"Presentation by Assertio Holdings, Inc." |
|
| 05/20/2020 |
8-K
| Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Fa...|
Docs:
|
"Agreement and Plan of Merger, by and among Zyla Life Sciences, Alligator Zebra Holdings, Inc., Assertio Therapeutics, Inc., Zebra Merger Sub, Inc. and Alligator Merger Sub, Inc. (Certain schedules (or similar attachments) to the Agreement and Plan of Merger have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant agrees to furnish copies of any such schedules (or similar attachments) to the U.S. Securities and Exchange Commission or its staff upon request.)",
"Fifth Amended and Restated Certificate of Incorporation of Zyla Life Sciences",
"Third Amended and Restated Bylaws of Zyla Life Sciences" |
|
| 05/20/2020 |
25
| Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securities: |
| 05/20/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 05/20/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 05/15/2020 |
8-K
| Quarterly results |
| 05/15/2020 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 05/15/2020 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 05/15/2020 |
8-K
| Quarterly results |
| 05/14/2020 |
10-Q
| Quarterly Report for the period ended March 31, 2020 |
| 05/01/2020 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2020 |
4/A
| McInnis Joe (Director) has filed a Form 4 on Zyla Life Sciences|
Txns:
| Exercised 6,667 shares
@ $1.75, valued at
$11.7k
Exercised 6,667 restricted stock units
@ $0 |
|
| 04/28/2020 |
4/A
| Walbert Timothy P (Director) has filed a Form 4 on Zyla Life Sciences|
Txns:
| Exercised 6,667 shares
@ $1.75, valued at
$11.7k
Paid exercise price by delivering 1,805 shares
@ $1.75, valued at
$3.2k
Exercised 6,667 restricted stock units
@ $0 |
|
| 04/28/2020 |
4/A
| Smiley Andrea Heslin (Director) has filed a Form 4 on Zyla Life Sciences|
Txns:
| Exercised 6,667 shares
@ $1.75, valued at
$11.7k
Paid exercise price by delivering 1,805 shares
@ $1.75, valued at
$3.2k
Exercised 6,667 restricted stock units
@ $0 |
|
| 04/28/2020 |
4/A
| Pauls Matthew (Director) has filed a Form 4 on Zyla Life Sciences|
Txns:
| Exercised 6,667 shares
@ $1.75, valued at
$11.7k
Paid exercise price by delivering 1,805 shares
@ $1.75, valued at
$3.2k
Exercised 6,667 restricted stock units
@ $0 |
|
| 04/27/2020 |
10-K/A
| Annual Report for the period ended December 31, 2019 [amend] |
| 04/24/2020 |
4
| Walbert Timothy P (Director) has filed a Form 4 on Zyla Life Sciences|
Txns:
| Exercised 6,667 shares
@ $1.75, valued at
$11.7k
Paid exercise price by delivering 952 shares
@ $1.75, valued at
$1.7k
Exercised 6,667 restricted stock units
@ $0 |
|
| 04/24/2020 |
4
| Smiley Andrea Heslin (Director) has filed a Form 4 on Zyla Life Sciences|
Txns:
| Exercised 6,667 shares
@ $1.75, valued at
$11.7k
Paid exercise price by delivering 952 shares
@ $1.75, valued at
$1.7k
Exercised 6,667 restricted stock units
@ $0 |
|
| 04/24/2020 |
4
| Pauls Matthew (Director) has filed a Form 4 on Zyla Life Sciences|
Txns:
| Exercised 6,667 shares
@ $1.75, valued at
$11.7k
Paid exercise price by delivering 952 shares
@ $1.75, valued at
$1.7k
Exercised 6,667 restricted stock units
@ $0 |
|
| 04/24/2020 |
4
| McInnis Joe (Director) has filed a Form 4 on Zyla Life Sciences|
Txns:
| Exercised 6,667 shares
@ $1.75, valued at
$11.7k
Paid exercise price by delivering 952 shares
@ $1.75, valued at
$1.7k
Exercised 6,667 restricted stock units
@ $0 |
|
| 04/20/2020 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/13/2020 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
|